PPMD Community

All Blog Posts Tagged 'Staff' (555)


Staff
Congress Calls on FDA to Increase Efforts to Treat Duchenne



Thanks to this incredible community urging lawmakers, well over 100 Members of Congress signed and submitted a letter …

Continue

Added by Ryan Fischer on February 18, 2016 at 2:40pm — 1 Comment


Staff
Duchenne Dental Dilemmas: Bisphosphonates & Osteonecrosis of the Jaw

Medication-related osteonecrosis of the jaw (MRONJ),  or osteonecrosis of the jaw (ONJ), is a condition that results when the bones of the jaw are exposed and then do not heal  generally when a tooth is removed.…

Continue

Added by Kathi Kinnett on February 11, 2016 at 11:30am — No Comments


Staff
PPMD Announces Gene Therapy Forum

This year’s already action-packed Advocacy Conference, February 21-23 welcomes a special Gene Therapy Forum on Monday, February…

Continue

Added by Abby Bronson on February 10, 2016 at 10:30am — 2 Comments


Staff
Update on Summit Clinical Trials

Summit Therapeutics’ SMT C1100 is a small molecule drug that targets increasing the production of utrophin. Utrophin is a protein that is present in early muscle development but “switched off” as muscle fibers mature and dystrophin is…

Continue

Added by Ann Martin on February 9, 2016 at 1:00pm — No Comments


Staff
PDUFA Extension for the FDA's Review of Eteplirsen

Sarepta Therapeutics received notification of a PDUFA extension for the FDA's review of eteplirsen. The PDUFA date was extended by an…

Continue

Added by PPMD on February 8, 2016 at 10:00am — No Comments


Staff
ACTION ALERT: Sign-On Extended! Urge House Member - Apply FDASIA Tools to Duchenne

Action Alert

PPMD and a coalition of Duchenne foundations continue to work together on preparing for the Sarepta Ad Comm. As of today, we are still waiting on a new confirmed date. With the postponement of the Ad Comm, the Congressional letter to FDA remains open. Has your House Members signed on…

Continue

Added by Ryan Fischer on January 25, 2016 at 11:30am — No Comments


Staff
FDA Ad Comm for Eteplirsen Postponed Due to Inclement Weather

We are deeply saddened, disappointed, and distressed to report that the highly-anticipated Ad Comm for eteplirsen has been postponed due to the blizzard anticipated to hit DC on Friday. We are grateful to our extraordinarily powerful Duchenne community who has been willing to travel into the eye of this storm to fight Duchenne. Our community has proven once again to be a force stronger than any winter storm, and much stronger than Duchenne itself. As soon as we receive any updates…

Continue

Added by PPMD on January 20, 2016 at 7:09pm — No Comments


Staff
ACTION ALERT: Urge House Member - Apply FDASIA Tools to Duchenne

There has never been a moment like this in our Duchenne community. Today the FDA released briefing documents on the application for eteplirsen. It is clear that we continue to face a serious regulatory challenge as a community.…

Action Alert

Continue

Added by Ryan Fischer on January 15, 2016 at 2:45pm — 1 Comment


Staff
Marathon Expanded Access Program for Deflazacort: FAQs

We know that many of you have questions regarding Marathon Pharmaceuticals and their expanded access program for deflazacort in the US. PPMD has reached out to the company to get answers to some of the questions. The FAQs below explain what…

Continue

Added by PPMD on January 15, 2016 at 12:30pm — No Comments


Staff
Briefing Documents for Sarepta’s Ad Comm Released

The briefing documents for Sarepta’s Ad Comm, one week from today, have been released. We will spend the…

Continue

Added by PPMD on January 15, 2016 at 11:46am — No Comments


Staff
Wisdom teeth & Duchenne

The removal of “wisdom teeth” (third molars) is one of the most common procedures performed by oral and maxillofacial surgeons. While it is common, it is considered…

Continue

Added by Kathi Kinnett on January 15, 2016 at 9:30am — No Comments


Staff
A Blow to Our Community – But Our Work Continues

Today our community was dealt a painful blow as the FDA issued a Complete Response letter to BioMarin regarding the company’s New Drug Application (NDA) for Kyndrisa (drisapersen). As stated in BioMarin’s press release, “The FDA issues Complete Response letters to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.  FDA…

Continue

Added by Pat Furlong on January 14, 2016 at 12:30pm — 3 Comments


Staff
PPMD Responds to Revisions to “The Common Rule”

The Common Rule – or the 'Federal Policy for the Protection of Human Subjects' – is a human subjects biomedical and behavioral ethics rule that sets the ethical standards by which all…

Continue

Added by Annie Kennedy on January 13, 2016 at 1:58pm — No Comments


Staff
Standard Operating Procedures for Duchenne Animal Models, Published

In 2012, PPMD hosted a meeting with NHLBI entitled Contemporary Issues in Duchenne Cardiology. One of the small groups resulting from that meeting – the Animal Model Small Group – was tasked with…

Continue

Added by Kathi Kinnett on January 13, 2016 at 1:00pm — No Comments


Staff
Duchenne History in the Making — and We Need You to Join Us! | January 22, 2016 | Silver Spring, MD

Next week, on January 22nd, an FDA Advisory Committee will review eteplirsen for potential approval and use within our Duchenne community.

The Duchenne community is joining forces in a show of strength to demonstrate to the FDA our community’s support for our robust therapeutic pipeline. All Duchenne community members are encouraged to attend the Advisory…

Continue

Added by Annie Kennedy on January 13, 2016 at 11:30am — No Comments


Staff
Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management

Dysphasia, or difficulty swallowing, effects many patients with Duchenne. Complaints of "something stuck in my throat" are not uncommon. Symptoms may progress to difficulty swallowing saliva, coughing during and after…

Continue

Added by Kathi Kinnett on January 8, 2016 at 9:23am — No Comments


Staff
Akashi Therapeutics Establishes International Partnership with Grünenthal Group on HT-100 for DMD

PPMD supported the development of the HT-100 program from early on, including a $500,000 investment via our GIFTED program for the clinical trial. We are excited for the expansion of the clinical trial and thrilled for the relationship with Grunenthal. This incredible partnership enables Akashi to continue to be managed and led by parents and we are all hopeful HT-100 will be part of the cocktail of combined therapies that will achieve our highest priority--to…

Continue

Added by PPMD on January 8, 2016 at 9:02am — No Comments


Staff
FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy

FibroGen announced enrollment of their first patients in an open-label, multicenter Phase 2 clinical trial of the investigational compound FG-3019 in non-ambulatory patients with Duchenne. We are thankful that FibroGen is addressing ways to treat fibrosis caused by Duchenne’s progression and are hopeful that this study will prove promising.

Learn more about FibroGen and FG-3019…

Continue

Added by PPMD on January 7, 2016 at 10:00am — No Comments


Staff
We did it! Over $270,000 raised to support early-stage research.

Last month we told you we hoped to raise $200,000 to support new, early-stage research. Throughout the month, we told you about potential therapies like epicatechin. We told you about generous matches from Mary-Lou and Larry Weisman and the Dumm Family/…

Continue

Added by Pat Furlong on January 5, 2016 at 11:00am — No Comments


Staff
Finding Hope in CRISPR/Cas9

Strategies that address the basic problem in Duchenne, the absence of dystrophin, are critically important to patients and families and have attracted considerable attention from drug developers.

 

We already have two technologies – exon skipping and stop…

Continue

Added by PPMD on January 4, 2016 at 1:30pm — 5 Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Need help using this community site? Visit Ning's Help Page.

Members

© 2016   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service